As a leading custom service provider in the antibody field, Creative Biolabs provides comprehensive analysis services for complete functional evaluation of your bispecific antibodies (BsAbs). Taking advantage of the state-of-the-art instruments, our experienced staff in analytical project design, equipment operation and data analysis can assist every customer to solve BsAb functional analysis problems. Creative Biolabs offers a variety of functional analysis services, including Affinity Measurement, ADCC Assay, CDC Assay, and ADCP Assay.
Antigen-antibody interactions produced by a combination of hydrophobic interactions, hydrogen bonds, electrostatic and van der Waals forces, which are non-covalent and reversible. Affinity is usually mentioned when describing the strength of the antigen-antibody complex. Understanding binding affinity is essential in studying the intermolecular interactions driving biological processes, the structural biology, and the structure-function relationships. Moreover, it is also determined as part of the drug discovery process to help design drugs that selectively bind their targets. Creative Biolabs offers several advanced techniques for affinity measurement of BsAbs, such as Surface Plasmon Resonance (SPR), ELISA-based Assay, and Flow Cytometry Assay.
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important cell killing mechanism of antibody drugs. Besides, for certain therapeutic bispecific IgGs and Fc-containing BsAbs, ADCC plays an essential role in their in vivo efficacy. Generally, ADCC tests are performed using two types of effector cells, the peripheral blood mononuclear cells (PBMCs) and NK cells. In addition, the 51Cr approach and the LDH approach are widely adopted to determine the extent of cell lysis. Creative Biolabs offers high quality ADCC assays for customers with either the 51Cr approach or the LDH approach and our tests will greatly contribute to the efficacy profiles of your therapeutic antibodies.
Figure 1. Mechanisms of action of monoclonal antibodies targeting surface antigens on MM cells (van de Donk, N. W., 2015).
Complement dependent cytotoxicity (CDC) is another crucial killing mechanism of antibody drugs. It is very crucial for the optimal function of therapeutic monoclonal antibodies (mAb) and is extremely conserved even after a chemotherapy treatment. A CDC assay evaluates the efficacy of candidates to initiate a multi-pathway attack which is mediated by the complement immune system to kill specific target cells. Commonly, CDC determines cell death via pre-loading the target cells with a radioactive compound. As cells die, the radioactive compound is released from them. Creative Biolabs offers highly reproducible CDC assays for the analysis and interpretation of the cytotoxic effects of your BsAbs.
ADCP is a potentially powerful mechanism of action (MOA) for antibody drug developers and vaccine makers to consider when measuring the product efficacy. It has been indicated that ADCP is improved in vivo by simultaneous treatment with immunomodulatory agents. Creative Biolabs has developed a reporter-gene assay that enables fast and more reliable measurement of ADCP of drug candidates. We are confident in providing unique ADCP assay services to meet customers’ requirements.
With our well-established function analysis platform, the experienced scientists at Creative Biolabs are dedicated to helping you develop therapeutic BsAbs. Our high-quality function analysis services will greatly contribute to the success of your projects. We also provide various other services regarding BsAbs development. Please feel free to contact us for more information and a detailed quote.
1. van de Donk, N. W.; et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2015, 127(6): 681-95.
2. Del Bano, J.; et al. Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Antibodies. 2016, 5(1): 1.
3. Jang, Y. Y.; et al. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells. Annals of Clinical & Laboratory Science. 2012, 42(1): 42-49.